target audience: TECH BUYER Publication date: Oct 2022 - Document type: IDC FutureScape - Doc Document number: # US48585622
IDC FutureScape: Worldwide Life Sciences 2023 Predictions
Table of Contents
-
IDC FutureScape Figure
-
Figure: IDC FutureScape: Worldwide Life Sciences 2023 Top 10 Predictions
-
-
Executive Summary
-
IDC FutureScape Predictions
-
Summary of External Drivers
-
Predictions: Impact on Technology Buyers
-
Prediction 1: By the End of 2024, Transparency Improvements Driven by Drug Serialization and Traceability Mandates Will Translate into 20% Reduction in Revenue Leakage at Life Science Companies Worldwide
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 2: By 2025, 50% of Life Science Organizations Will Adopt Intelligent Tech Platforms to Embrace Sustainability-by-Design Strategies and Track Value Chain Emissions Across Sites, Processes, and Products
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 3: By 2025, 80% of Pharma Will Have Adopted AI-Enabled Pharmacovigilance Solutions with "Human in the Loop" to Avoid "Black Swan Events," Drive Patient Safety, and Support Value-Based Pricing
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 4: By 2025, 60% of Life Science Firms Will Use Health Data Platforms for Physician Engagement and Patient Journey Processes, 65% to Support Regulatory Submissions, and 35% to Support Value-Based Pricing
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 5: By 2026, Investments in Integrated Supply Chain Management Will Enable Half of Global Life Science Manufacturers to Increase Revenue by Avoiding Stockouts of Active Ingredients and Supplies
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 6: By 2026, the Adoption of AI-Based Drug Design by the Life Science Industry Will Grow by 65%, Fueled by a Focus on Precision Medicine and a Fast-Growing Ecosystem of Innovative Tech Start-Ups
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 7: By 2027, Investments in Digital Pathology Multimodal Data Integration Capabilities Will Double to Advance Cancer Diagnostics, Define Composite Biomarkers, and Drive a Precision Medicine Strategy
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 8: By the End of 2027, 95% of Pharma Companies Will Have Established Strategic Partnerships to Access Real-World Data, with 25% Transitioning to the Adoption of Synthetic Data
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 9: Pioneered by the United States, Retail Pharmacies Will Fuel Diversity and Inclusion, Increasing Access to Clinical Trials by 60%, Enabling a Care Anywhere Strategy, and Driving Adoption of CRAACO by 2028
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 10: By 2028, 60% of Life Science Organizations Will Have Adopted the Metaverse with Early Adoption for HCP Engagement, Training, and Sales Enablement, with Gradual Adoption in Digital Therapeutics
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
-
Advice for Technology Buyers
-
External Drivers: Detail
-
Storms of Disruption — Accelerating, Interconnected Uncertainty
-
Cybersecurity and Risk — Scaling and Evolving Threat Environment
-
Global Supply Shock — Refocusing on Multisource and Resilience
-
Digital Business — Stepping Stone to the Future Enterprise
-
Meaningful Intelligence — Differentiated Decision Power
-
Embracing the Metaverse — New Levels of Immersion
-
Mainstream ESG — Sustainability Is Measured and Mandatory
-
-
Learn More
-
Related Research
-